Esperion Therapeutics, Inc. Presents Full Results Of Phase 2 Clinical Study Demonstrating That ETC-1002 Lowered LDL-C By An Average Of 32 Percent And Was Well Tolerated In Patients With Hypercholesterolemia And History Of Statin Intolerance

Esperion Therapeutics, Inc. (Nasdaq:ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced full results of a Phase 2 clinical study of its lead product candidate ETC-1002 in patients with hypercholesterolemia and a history of statin intolerance.

Help employers find you! Check out all the jobs and post your resume.